Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Fortune III who wrote (1212)	6/9/1998 12:38:00 PM
From: advinfo	Respond to of 2887

In my opinion, we will not see a strong upward movement on ABMI until new investors start bring in new money. It will take some positive news and a much greater exposure of ABMI to make this happen. IMO, the road show in San Diego could be the catalyst that will provide the investors, news, and exposure you're looking for. Great move by Rash and company to help get the spotlight on ABMI. NorthStar

To: Bill Fortune III who wrote (1212)	6/16/1998 10:19:00 AM
From: Jeffrey L. Henken	Read Replies (4) \| Respond to of 2887

BSX purchases Scneider today. How will AVE continue to compete? How about JNJ and the other players in this field? ABMI could be next on the acquisition block. Remember we are merely speculating but there certainly is plenty of evidence that would seem to make American BioMed and excellent acquisition choice for AVE. Like what you say? First off AVE does not have a catheter bundled with AVE's stents yet. They recently bought World Medical which does not have a proven product line either other than some catheters for $62 million. Basically they were purchased for their AAA Talent stent system. If you ask me to date AVEI is still a one trick pony. A very good pony but they could still use a broader portfolio. I have read post after post at the Yahoo AVEI thread that confirms that AVEI does not yet bundle their stents with a catheter. American BioMed's OmniStent designs are very similar to the stents that World Medical currently has in phase II testing. Will AVE use a catheter designed by World Medical to deliver these stents as well as their current designs? Are they are looking to an outside source for catheters that could be quickly designed for this purpose: American BioMed's catheters could be just the ticket. Will that happen? Probably not, I'll admit that it probably won't happen but it's possible. What other products do they have that might round out AVEI's product line? How about the OmniCath? Dr Summers and I discussed some of the advantages last night at Yahoo. Arterial Vascular Engineering has no atherectomy device. Neither does JNJ. New protocols for the OmniCath are set for the phase II trials will be starting again. The markets that this atherectomy device will compete in are in excess of $500 million according to American Biomed's calculations when it is approved for all hoped for uses. americanbiomed.com biz.yahoo.com biz.yahoo.com Perhaps the Guidewire MicroFilter(OmniFilter) which also will address a market as high as $500 million starting in early 1999. The Company has developed a percutaneous temporary filter which is mounted on a guide wire and is used to prevent stroke-causing blood clots from reaching various organs of the human body. americanbiomed.com americanbiomed.com American BioMed also has the OmniStent technology which could enter phase I testing this year. These stent designs are very similar to World Medicals. The bifurcated OmniStent™ is a Y-shaped bifurcated stent designed for use in aortic bifurcation. However, small versions may be used at any branched blood vessel: americanbiomed.com biz.yahoo.com American BioMed estimates that it's products compete in a $10 Billion market. Their silicone catheters no doubt have to compete more on the basis of price and performance than the fact they won't fragment if they fracture or cause an allergic reaction. Still they do have those added advantages. American BioMed presented at the National Vascular Meeting in San Diego last week. All indication are that it was a huge success. Dr Ahn was there and held a workshop on the use of American BioMed catheters. It was essentially the coming out party for the Ahn Thrombectomy Catheter. Today's purchase of Schneider by BSX pushes AVE and other companies in this field closer to acquisitions of their own. ABMI could be had for a whole lot less than the $2.1 billion that Schneider went for today. ABMI has a broader product line. It would be a great fit. GO ABMI! Regards, Jeff